Camurus AB (Sweden) Performance
| CAMX Stock | SEK 573.00 12.00 2.14% |
The firm shows a Beta (market volatility) of 0.71, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Camurus AB's returns are expected to increase less than the market. However, during the bear market, the loss of holding Camurus AB is expected to be smaller as well. At this point, Camurus AB has a negative expected return of -0.28%. Please make sure to confirm Camurus AB's jensen alpha, treynor ratio, value at risk, as well as the relationship between the total risk alpha and maximum drawdown , to decide if Camurus AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Camurus AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 461.8 M | |
| Total Cashflows From Investing Activities | -4.9 M |
Camurus |
Camurus AB Relative Risk vs. Return Landscape
If you would invest 70,400 in Camurus AB on August 25, 2024 and sell it today you would lose (13,100) from holding Camurus AB or give up 18.61% of portfolio value over 90 days. Camurus AB is generating negative expected returns and assumes 2.5898% volatility on return distribution over the 90 days horizon. Simply put, 23% of stocks are less volatile than Camurus, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Camurus AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Camurus AB's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Camurus AB, and traders can use it to determine the average amount a Camurus AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1072
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CAMX |
Estimated Market Risk
| 2.59 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.28 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Camurus AB is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Camurus AB by adding Camurus AB to a well-diversified portfolio.
Camurus AB Fundamentals Growth
Camurus Stock prices reflect investors' perceptions of the future prospects and financial health of Camurus AB, and Camurus AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Camurus Stock performance.
| Return On Equity | 0.0317 | |||
| Return On Asset | 0.0146 | |||
| Profit Margin | 0.03 % | |||
| Operating Margin | 0.03 % | |||
| Current Valuation | 14.22 B | |||
| Shares Outstanding | 55.42 M | |||
| Price To Earning | (34.91) X | |||
| Price To Book | 15.19 X | |||
| Price To Sales | 18.23 X | |||
| Revenue | 600.57 M | |||
| EBITDA | (97.72 M) | |||
| Cash And Equivalents | 411.57 M | |||
| Cash Per Share | 7.74 X | |||
| Total Debt | 18.93 M | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 17.49 X | |||
| Cash Flow From Operations | (143.43 M) | |||
| Earnings Per Share | 0.45 X | |||
| Total Asset | 1.08 B | |||
| Retained Earnings | 13 M | |||
| Current Asset | 750 M | |||
| Current Liabilities | 176 M | |||
About Camurus AB Performance
Assessing Camurus AB's fundamental ratios provides investors with valuable insights into Camurus AB's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Camurus AB is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Camurus AB , a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company was founded in 1991 and is headquartered in Lund, Sweden. Camurus AB operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 140 people.Things to note about Camurus AB performance evaluation
Checking the ongoing alerts about Camurus AB for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Camurus AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Camurus AB generated a negative expected return over the last 90 days | |
| The company reported the revenue of 600.57 M. Net Loss for the year was (110.57 M) with profit before overhead, payroll, taxes, and interest of 515.22 M. | |
| Camurus AB has accumulated about 411.57 M in cash with (143.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.74. | |
| Roughly 51.0% of the company shares are held by company insiders |
- Analyzing Camurus AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Camurus AB's stock is overvalued or undervalued compared to its peers.
- Examining Camurus AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Camurus AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Camurus AB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Camurus AB's stock. These opinions can provide insight into Camurus AB's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Camurus Stock Analysis
When running Camurus AB's price analysis, check to measure Camurus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Camurus AB is operating at the current time. Most of Camurus AB's value examination focuses on studying past and present price action to predict the probability of Camurus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Camurus AB's price. Additionally, you may evaluate how the addition of Camurus AB to your portfolios can decrease your overall portfolio volatility.